AR128382A1 - Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidor de respuesta de daños de dna - Google Patents
Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidor de respuesta de daños de dnaInfo
- Publication number
- AR128382A1 AR128382A1 ARP230100211A ARP230100211A AR128382A1 AR 128382 A1 AR128382 A1 AR 128382A1 AR P230100211 A ARP230100211 A AR P230100211A AR P230100211 A ARP230100211 A AR P230100211A AR 128382 A1 AR128382 A1 AR 128382A1
- Authority
- AR
- Argentina
- Prior art keywords
- mammal
- group
- radiopharmaceutical
- dna damage
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304178P | 2022-01-28 | 2022-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128382A1 true AR128382A1 (es) | 2024-04-24 |
Family
ID=87469883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100211A AR128382A1 (es) | 2022-01-28 | 2023-01-30 | Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidor de respuesta de daños de dna |
Country Status (12)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4355325A4 (en) * | 2021-06-16 | 2025-05-07 | Fusion Pharmaceuticals Inc. | COMBINATION OF A NEUROTENSIN RECEPTOR-BINDING COMPOUND AND FOLFIRINOX |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2478695B1 (es) * | 2012-12-20 | 2015-04-28 | Servicio Andaluz De Salud | Dispositivo para inducir hipotermia terapéutica |
| KR20210099073A (ko) * | 2018-12-03 | 2021-08-11 | 퓨전 파마슈티칼즈 인크. | 방사성면역접합체와 체크포인트 억제제의 조합 요법 |
-
2023
- 2023-01-27 JP JP2024544710A patent/JP2025503215A/ja active Pending
- 2023-01-27 CA CA3249955A patent/CA3249955A1/en active Pending
- 2023-01-27 MX MX2024009312A patent/MX2024009312A/es unknown
- 2023-01-27 IL IL314530A patent/IL314530A/en unknown
- 2023-01-27 CN CN202380029883.6A patent/CN119136846A/zh active Pending
- 2023-01-27 AU AU2023211719A patent/AU2023211719A1/en active Pending
- 2023-01-27 KR KR1020247028703A patent/KR20240142499A/ko active Pending
- 2023-01-27 US US18/833,849 patent/US20250177581A1/en active Pending
- 2023-01-27 WO PCT/CA2023/050108 patent/WO2023141717A1/en not_active Ceased
- 2023-01-27 EP EP23745772.6A patent/EP4469092A1/en active Pending
- 2023-01-30 TW TW112103192A patent/TW202337451A/zh unknown
- 2023-01-30 AR ARP230100211A patent/AR128382A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4469092A1 (en) | 2024-12-04 |
| JP2025503215A (ja) | 2025-01-30 |
| TW202337451A (zh) | 2023-10-01 |
| MX2024009312A (es) | 2024-08-06 |
| US20250177581A1 (en) | 2025-06-05 |
| CA3249955A1 (en) | 2023-08-03 |
| AU2023211719A1 (en) | 2024-08-15 |
| KR20240142499A (ko) | 2024-09-30 |
| WO2023141717A1 (en) | 2023-08-03 |
| CN119136846A (zh) | 2024-12-13 |
| IL314530A (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wardman | Chemical radiosensitizers for use in radiotherapy | |
| JP7217752B2 (ja) | Acss2阻害剤およびその使用方法 | |
| ES2165830T1 (es) | Kit para radiomarcar proteinas con itrio-90. | |
| AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
| BR0210971A (pt) | Formas inovadoras de dosagem de benzimidazol substituìdo e método para usar as mesmas | |
| DOP2002000333A (es) | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz | |
| HRP20240952T1 (hr) | Spojevi koji ciljaju psma i njihova uporaba | |
| EP4545143A3 (en) | Early intervention methods to prevent or ameliorate toxicity | |
| US20100022514A1 (en) | Heterocycle Compounds and Methods of Use Thereof | |
| SK286676B6 (sk) | Použitie ftalazínových derivátov | |
| AR067850A1 (es) | Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit | |
| MX9303441A (es) | Procedimiento para la preparacion de acido clavulanico. | |
| AR063869A1 (es) | Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante | |
| Boughton et al. | Alarin stimulates food intake and gonadotrophin release in male rats | |
| Fukuda et al. | Kinetics of porphyrin accumulation in cultured epithelial cells exposed to ALA. | |
| US20130012709A1 (en) | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES | |
| BR112017012841A2 (pt) | complexos radiofarmacêuticos | |
| AR128381A1 (es) | Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidores punto de control | |
| BRPI0713013A2 (pt) | compostos orgánicos | |
| AR128385A1 (es) | Radiofármacos dirigidos al psma e inhibidor de punto de control | |
| WO2024078568A1 (zh) | Akr1c3激活抗癌前药化合物与镇痛药物联用治疗伴有疼痛的癌症患者 | |
| DK360584A (da) | Triazol-pyrimidinderivater og fremgangsmaade til fremstilling deraf samt disses terapeutiske anvendelse som cardiotoniske midler | |
| MX2024009312A (es) | Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidor de respuesta de da?os de dna. | |
| AR132418A1 (es) | Agentes radiofarmacéuticos dirigidos a psma y terapia de combinación con inhibidores de la respuesta al daño de adn | |
| WO2018039581A1 (en) | Use of hdac6 inhibitors for preventing and treating renal cystogenesis, renal cell carcinoma, and renal ciliopathies |